5 results about "Fusidic acid" patented technology

The invention discloses a method for reducing the content of an M impurity in fusidic acid fermentation liquor. The generation of the M impurity is inhibited from a fermentation source by optimizing a fermentation culture medium and regulating and controlling pH in stages. A fermentation culture medium adopts a composite organic nitrogen source, contains soybean cake powder with specific grease content, and is matched with a yeast extract and corn steep liquor, so that a key precursor can be provided for fusidic acid synthesis, and the enzyme activity can be regulated; the pH is regulated in the early stage of fermentation to adapt to the proliferation requirement of the strain, M impurity synthesis is preliminarily inhibited, the pH is regulated in the middle and later stages to strengthen the activity of a target product synthetase, and M impurity synthetase expression is remarkably inhibited. The process is simple, subsequent complex purification is not needed, the yield of fusidic acid is increased, M impurities are reduced to 2% or below, and the method is suitable for industrial large-scale production.

Provided herein are compositions for topical application to a subject for the treatment of epidermolysis bullosa (EB). Also disclosed are methods for treating skin in a human with EB. The methods comprise providing a composition comprising fusidic acid and one or more pharmaceutically acceptable excipients; and topically applying, or instructing the topical application of, the composition to the skin of a human with EB. In certain embodiments, the composition is topically administered to treat non-healing wounds, chronic wounds, or diseased skin in a patient with EB, to reduce the likelihood of skin infection, to reduce the likelihood of scarring, to prevent or reduce the risk of an infected skin blister, to treat intact blisters on the skin, to treat skin dysbiosis, to alter bacterial diversity of the skin microbiome, or to improve the quality of life of a subject with EB.

The application provides a method for extracting fusidic acid hemihydrate from fusidic acid bacterial residue, belongs to the field of fermentation engineering, and reutilizes the bacterial residue after separation of an extraction liquid, breaks through the limitation of separation and purification of the extraction liquid in the prior art, and significantly improves the potency, yield, energy saving and emission reduction and pollution reduction of the preparation of fusidic acid.

The invention discloses a fusidic acid C-3-site oxazole substituted, C-24-site reduced and C-21-site benzyl ester modified derivative as well as a preparation method and application thereof, and belongs to the technical field of organic chemistry. The structure of the fusidic acid derivative with oxazole substitution at the C-3 site, reduction at the C-24 site and benzyl ester modification at the C-21 site is shown in the specification, wherein R represents 3-methyl benzyl, 3-chlorobenzyl, 2-bromobenzyl, 3-bromobenzyl or 4-cyanobenzyl. The fusidic acid derivative provided by the invention has the beneficial effects that the MDR reverse activity of the fusidic acid derivative substituted at C-3 position by oxazole, reduced at C-24 position and modified by benzyl ester at C-21 position is excellent, the druggability is better, and the fusidic acid derivative can be combined with common antitumor drugs to play a good antitumor role in clinical treatment.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to fusidic acid gel based on a deep eutectic solvent (DES) and a preparation method of the fusidic acid gel. The invention aims to solve the problems that the stability of cream is poor, and the curative effect is poor due to the fact that raw materials exist in a suspension form. According to the invention, a plurality of deep eutectic solvents are firstly screened, and it is accidentally found that DES formed by taking glycerol as a hydrogen bond acceptor and arginine as a hydrogen bond donor has the best dissolution effect on fusidic acid, and the dissolution effect is far better than that of traditional solvents and other types of DES. Based on the discovery, the fusidic acid gel provided by the invention is prepared by taking the preferable DES as a core component, dissolving the medicine at high concentration, and then mixing with a gel matrix for forming. The preparation is simple in preparation process, green and safe, and has the advantages of high stability, efficient in-vitro release, remarkable antibacterial ability and the like.